Michael Chen, DO
Neurology · Council Bluffs, IANPI 1205859170
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 593 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 49 manufacturers reported payments, led by AbbVie at 24.7% of the total. 2025 is the largest year on record at $2,952, 3.4 times the $869 reported in 2019.
Across 593 payments — averaging $15.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Lilly USA, LLC$824
- UCB, Inc.$586
- Lundbeck LLC$515
- Novartis$426
- Eisai Inc.$423
- plus $4K from 43 others
What the payments were for
- Food & beverage$9,393100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Leqembi$122
How this compares
$9,393 in reported general payments places this provider in the 85th percentile of 132 neurology providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 39 | $310,653 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 42 | $135,154 |
| TecfideraDimethyl Fumarate | 13 | $120,816 |
| Nurtec OdtRimegepant Sulfate | 70 | $118,004 |
| AustedoDeutetrabenazine | 17 | $116,019 |
| Aimovig AutoinjectorErenumab-Aooe | 125 | $105,891 |
| QuliptaAtogepant | 94 | $92,706 |
| UbrelvyUbrogepant | 58 | $83,664 |
| Emgality PenGalcanezumab-Gnlm | 97 | $76,400 |
| NuplazidPimavanserin Tartrate | 12 | $59,957 |
| FycompaPerampanel | 26 | $30,745 |
| BriviactBrivaracetam | 22 | $30,469 |
| KeppraLevetiracetam | 12 | $20,799 |
| Dimethyl Fumarate | 16 | $20,071 |
| AptiomEslicarbazepine Acetate | 12 | $16,028 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $258 | $310,65339 claims |
| AbbVieQulipta, Ubrelvy | $2,317 | $176,371152 claims |
| Grifols USA, LLCGamunex-C | $53 | $135,15442 claims |
| PfizerNurtec Odt, Lyrica | $369 | $132,72989 claims |
| BiogenTecfidera | $153 | $120,81613 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $319 | $116,01917 claims |
| Acadia Pharmaceuticals IncNuplazid | $399 | $59,95712 claims |
| Eisai Inc.Fycompa | $423 | $30,74526 claims |
| UCB, Inc.Briviact | $586 | $30,46922 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $45 | $16,02812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 132 neurology providers in Iowa.
Other neurology in Council Bluffs
- Bruce HughesDes Moines$1.8M
- Michael JacobyDes Moines$243K
- Lynn RankinDes Moines$181K
- Winthrop RiskCedar Rapids$136K
- Wendy ZadehDes Moines$134K
- Paul BabikianDes Moines$107K
- Scott GeislerCedar Rapids$87K
- Douglas NathansonIowa City$47K
- Mark PuricelliDes Moines$45K
- Rahul KhannaWest Burlington$38K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.